Due to the benefits of neoadjuvant chemotherapy (NACT) for patients with advanced GC, there has been interest in adding trastuzumab to the perioperative treatment of HER2(+) locally advanced GC in the past decade. This evidence concerns the gene ERBB2 and gastric cancer.